|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Opko Health, Inc. Catches Investors' Attention With Alzheimer's Test
5/14/2012 8:20:58 AM
As Pfizer’s rheumatoid arthritis pill and Arena Pharmaceuticals’ weight-loss drug got positive nods from federal advisory panels, the role of biotech companies in finding new treatments for major medical disorders is getting renewed investor attention. An advisory group at the Food and Drug Administration recommended approval of Pfizer’s drug, known as tofacitinib, which could possibly revive sales after the company’s blockbuster cholesterol drug, Lipitor, lost its patent last year. And another FDA advisory panel’s positive recommendation on Arena’s diet drug, lorcaserin, could possibly end up getting approved by the agency, which would be the first new prescription diet pill that would be marketed in 13 years. In February, another obesity drug, Qnexa, developed by Vivus, was also endorsed by the same FDA panel.
|
|
|
|
|
|
|
|
|
|
|